Reading through the report in more detail the following was of particular interest. FTO levels appear to be x3 times the pre-radio therapy levels. this could easily result in benefits with all Radio-therapies + any cancer resistance caused by ferroptosis. As with Decitabine, the treatment itself upregulates FTO and thus aids in Zantrene wiping out the cancer via FTO inhibition. From the study a similar thing occurs with Radio-therapy and not just ferroptosis caused by NPC.
Source: m6A demethylase FTO renders radioresistance of nasopharyngeal carcinoma via promoting OTUB1-mediated anti-ferroptosis - ScienceDirect
Whilst we await the Cardio protect results, I can only speculate on the MOA. But if this extends to other treatments beyond Dox and Carfilzomib that would be astonishing. Also cardio-renal indications can benefit greatly from cardio protection - if Zantrene's MOA works across the board.
The list goes on and on, is this what immuno-therapy research first started out like?
General Comments / Chat, page-6075
-
- There are more pages in this discussion • 5,333 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.020(1.20%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $177.8K | 108.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |